London - Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has launched Midazolam in 0.9% Sodium Chloride (NaCl) Injection bags, in 50mg/50mL and 100mg/100mL doses.

The product has been launched in the US and is indicated for continuous intravenous infusion for sedation of intubated and mechanically ventilated adult, pediatric, and neonatal patients as a component of anesthesia or during treatment in a critical care setting.

Hikma is a top three supplier of generic injectable medicines by volume in the US[1], with a growing portfolio of more than 150 products. We are continuously expanding our portfolio of essential medicines and introducing new dosage forms that enhance patient care.

This product has been approved for marketing in the United States by the US FDA. This product approval does not confer the right on Hikma, or any other party, to market this product outside the United States.

Contact:

Tel: +44 (0) 20 7399 2760

Fax: +44 (0) 20 7399 2761

(C) 2023 Electronic News Publishing, source ENP Newswire